Clinical Trial Detail

NCT ID NCT03189719
Title First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

esophagus squamous cell carcinoma

gastroesophageal junction adenocarcinoma

esophagus adenocarcinoma

Therapies

Cisplatin + Fluorouracil

Cisplatin + Fluorouracil + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.